Cargando…
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress
SIMPLE SUMMARY: Immune based treatments (ITs) represent one of the most important strategies in the treatment of acute myeloid leukemia (AML), like allogeneic stem cell transplant. Recently, several strategies have been explored: monoclonal antibodies (immunoconjugates or not, checkpoint inhibitors)...
Autores principales: | Molica, Matteo, Perrone, Salvatore, Andriola, Costanza, Rossi, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605302/ https://www.ncbi.nlm.nih.gov/pubmed/37894427 http://dx.doi.org/10.3390/cancers15205060 |
Ejemplares similares
-
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
por: Perrone, Salvatore, et al.
Publicado: (2023) -
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
por: Molica, Matteo, et al.
Publicado: (2021) -
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients
por: Molica, Matteo, et al.
Publicado: (2023) -
New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Gallazzi, Marco, et al.
Publicado: (2022) -
Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect
por: Perrone, Salvatore, et al.
Publicado: (2023)